Aquestive Therapeutics, Inc. (AQST) SEC Filing 8-K Material Event for the period ending Friday, May 13, 2022

Aquestive Therapeutics, Inc.

CIK: 1398733 Ticker: AQST

View differences made from one to another to evaluate Aquestive Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aquestive Therapeutics, Inc..


Assess how Aquestive Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aquestive Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Aquestive Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AQST
CIK: 1398733
Form Type: 8-K Corporate News
Accession Number: 0001140361-22-019495
Submitted to the SEC: Tue May 17 2022 7:25:29 AM EST
Accepted by the SEC: Tue May 17 2022
Period: Friday, May 13, 2022
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: